Long-Term Oral Treatment with Non-Hypoglycemic Dose of Glibenclamide Reduces Diabetic Retinopathy Damage in the Goto-KakizakiRat Model

Diabetic retinopathy (DR) remains a major cause of vision loss, due to macular edema, retinal ischemia and death of retinal neurons. We previously demonstrated that acute administration of glibenclamide into the vitreous, or given orally at a non-hypoglycemic dose, protected the structure and the fu...

Descripción completa

Detalles Bibliográficos
Autores principales: Berdugo, Marianne, Delaunay, Kimberley, Lebon, Cécile, Naud, Marie-Christine, Radet, Lolita, Zennaro, Léa, Picard, Emilie, Daruich, Alejandra, Beltrand, Jacques, Kermorvant-Duchemin, Elsa, Polak, Michel, Crisanti, Patricia, Behar-Cohen, Francine F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308933/
https://www.ncbi.nlm.nih.gov/pubmed/34371786
http://dx.doi.org/10.3390/pharmaceutics13071095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308933/
https://www.ncbi.nlm.nih.gov/pubmed/34371786
http://dx.doi.org/10.3390/pharmaceutics13071095

Ejemplares similares